Urge your members of Congress to support continued medical research funding
The bipartisan Medicare Access and CHIP Reauthorization Act (MACRA), signed into law April 2015, eliminated the Sustainable Growth Rate (SGR) and replaced it with the Quality Payment Program (QPP). Clinicians billing Medicare Part B, who meet the eligibility requirements, must participate in the QPP through one of two tracks: the Merit-based Incentive Payment System (MIPS) and Advanced Alternative Payment Models (APMS).
The information below provides an overview of MACRA and its impact on hematology.
Disclaimer: The information provided here is intended as a general overview and is not comprehensive.
Sign up to report data for MIPS through Healthmonix’s MIPSPRO, a 2017 Qualified MIPS Registry
Find out if you are exempt from participating in MIPS, learn how to avoid a negative payment adjustment in 2019, and more
A webinar providing an overview of the final rule and its impact on hematology
Frequently asked questions about the Medicare Access and CHIP Reauthorization Act
If you have additional questions related to MACRA, please contact ASH Policy and Practice Manager Leslie Brady at lbrady@hematology.org or 202-292-0264.
Blood: How I Treat Hematology 2017 ASH Academy ASH On Demand
Find educational and scientific meeting opportunities for hematology professionals worldwide.
Explore two interactive CML cases through an immersive simulated learning experience.
Increase awareness, knowledge, and confidence regarding the role of biosimilars in clinical care with a free online course.